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Abstract
Background: The increased number of childbearing women with autoimmune diseases leads to a growing interest
in studying relationship among maternal disease, therapy, pregnancy and off-spring. The aim of this study was to
determine the impact of autoimmune disease on pregnancy and on neonatal outcome, taking into account the
maternal treatment and the transplacental autoantibodies passage.
Methods: We studied 70 infants born to 70 pregnant women with autoimmune disease attended in Fondazione
IRCCS Policlinico San Matteo, Pavia, Italy from June 2005 to June 2012. Maternal and neonatal characteristics were
collected and relevant clinical, laboratory, therapeutics, sonographic and electrocardiographic investigations were
recorded and analyzed.
Results: We observed a high rate of spontaneous abortions in medical history, 29 %, and 18.6 % of preterm births
and 22.9 % of low birth weight (< 2500 g). Transplacental autoantibodies passage wasn’t related to maternal or
obstetrical complication, but anti-Ro/SSA positive pregnancies correlated with abnormal fetal heart rate (P = 0.01).
Pregnant women on therapy showed an higher incidence of maternal (p = 0.002), obstetric (p = 0.007)
complications and an increased rate of intrauterine growth restriction (p = 0.01) than the untreated ones.
Conclusions: Autoimmune diseases in pregnancy require to be carefully monitored to ensure the best possible
management of mothers, fetuses and newborns due to the high rate of morbidity specially in case of maternal
polytherapy and/or anti-Ro/SSA positivity.
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Background
Autoimmune diseases are a group of heterogeneous dis-
orders characterized by the attack of the immune system
against its own cells, tissue or organs. In this context the
resultant autoinflammatory reaction could be antibodies
mediated or cytokines/protein mediated, with conse-
quently multiple clinical and laboratory aspects [1]. Dis-
eases are more frequent in female gender than in male
(78 %) and they could become critical during pregnancy
when the immune system is actively involved to tolerate
a successful gestation process [2, 3]. A pregnant woman
with an autoimmune disease, should be considered high
risk because of the modulation of inflammatory process,
the possible effects of therapy on the fetus and the trans-
placental passage of autoantibodies [4, 5]. High fre-
quency of gestational and perinatal complications such
as preeclampsia, stillbirth, spontaneous abortions (11–
24 %), preterm birth (13.9 %) and intrauterine growth
restrictions (IUGR) (2.3 %) have been reported [6, 7].
Immunoglobulin G isotype antibodies can freely cross
the placenta with a linear relationship between gesta-
tional age and placental transfer [5]. Literature data
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report that anti-Ro/SSA and anti-La/SSB antibodies are
associated with neonatal lupus erythematosus and other
associated abnormalities such as congenital heart block
(CHB), cardiomyopathy, cutaneous lupus lesions, hepa-
tobiliary disease, and hematologic cytopenias [8, 9]. Fur-
thermore, an important issue concerns the use of drugs
to control maternal symptoms and exacerbations: these
substances and their metabolites can cross the placental
barrier and enter into the fetal circulation; this could in-
fluence the pregnancy progression, the fetus state and
the perinatal outcomes [4].
The aim of this study was to expose our experience
about the impact of autoimmune diseases on pregnancy,
fetus and neonate outcome, taking into account the
transplacental autoantibodies passage and the maternal
therapy.
Methods
This retrospective study was performed at Fondazione
IRCCS Policlinico San Matteo, Pavia, Italy from June
2005 to June 2012 and data of 70 women with a diag-
nosed autoimmune disease and of their 70 babies were
collected and analyzed. The hospital, located in the
north of Italy, is characterized by clinical, teaching and
research mission. All the women gave written informed
consent and the data was collected in a database and an-
alyzed as anonymous data for research purpose.
The study was approved by the Ethics Committee,
IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
All the enrolled women had a diagnosed autoimmune
diseases in our Division of Rheumatology according to
widely used criteria [10] and had a positive test for at
least one autoantibody. Exclusion criteria were: multiple
pregnancy, congenital infections, perinatal asphyxia,
chromosomal syndromes. Any abnormalities occurring
during pregnancy were registered as well as obstetrical
and maternal information. Blood tests to evaluate mater-
nal autoantibodies were performed during pregnancy ac-
cording to the clinical protocol used in our Department.
Neonatal gestational age, weight, length, head circum-
ference, Apgar score and cord pH were collected at birth
and adjusted for gestational and chronological age. Ma-
ternal and neonatal antinuclear autoantibodies (ANA)
were tested by a standard indirect immunofluorescence
technique, while anti-extractable nuclear antigen anti-
bodies (ENA) were evaluated by commercially available
ELISA kits. Cardiac and cerebral ultrasound scans were
performed in the neonate at birth, while electrocardio-
gram (ECG) testing was done within the first week of
life. Electrocardiographic parameters were evaluated
with particular attention to PR interval (nv <140 ms),
heart rate, QT interval corrected according to the
Bazett’s formula (QTc) (nv <440 ms): slightly extended if
the value is in the range of 440–470 ms and frankly ab-
normal if > 470 ms.
Statistical analysis
The Shapiro–Wilk test was used to test univariate nor-
mality of quantitative variables. When these were nor-
mally distributed, results were expressed as mean values
and SD, otherwise median values and interquartile range
were used (IQR; 25–75th percentile). Data were analyzed
adequately by Student t test or Mann–Whitney and by
analysis of variance (ANOVA) or Kruskal-Wallis test if
more than two groups were involved. All tests were two-
sided. P values ≤ 0.05 were considered statistically signifi-
cant. Association between quantitative variables was
evaluated by Spearman non parametric correlation.
Qualitative variables were described by counts and per-
centages and data were analyzed by Fisher’s exact test.
Data analysis was performed using STATA statistical
package (version 12; Stata Corporation, College Station,
2011, Texas, USA).
Results
Characteristics of the enrolled women are reported in
Table 1. Obstetrical history of 70 women revealed an in-
cidence of 29 % of miscarriages (40 out of 136
pregnancies).
Maternal complications observed among the 70 en-
rolled pregnant women were observed in 13 patients
Table 1 Characteristics of pregnant women
Mothers, number 70
Age, mean (SD) 33.3 years (5.1)
Pregnancy, number (%)
Term delivery (≥37 weeks) 57 (81.4)
Preterm delivery (<37 weeks) 13 (18.6)
Mode of delivery, number (%)
Vaginal delivery 33 (47.1)
Caesarean section 37 (52.9)
Autoimmune diagnosed disease, number (%):
Sjögren’s syndrome (SS) 8 (11.4)
Systemic lupus erithematosus (SLE) 9 (12.9)
Rheumatoid arthritis (RA) 3 (4.3)
Antiphospholipid syndrome (PAPS) 5 (7.1)
Undifferentiated connective tissue disease (UCTD) 19 (27.1)
Othersa 8 (11.4)
Not clinical manifest diseaseb 18 (25.7)
Drug therapy during pregnancy, number (%) 37 (52.9)
an = 1 autoimmune thyroiditis, n = 4 thrombocytopenia, n = 1 thyroiditis and
autoimmune gastritis, n = 1 ulcerative colitis, n = 1 Wegener’s granulomatosis.
All were ANA positive
bWomen positive to autoantibodies without clinical features of
autoimmune disease
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(19 %): 2 cases of gestational diabetes, 5 of hypertension,
1 of massive pulmonary embolism, 1 of hypertransami-
nasemia and hyperbilirubinemia, 1 of anemia and fur-
thermore, 1 autoimmune uveitis, 1 onset of Systemic
lupus erithematosus (SLE), 1 intrahepatic cholestasis due
to the worsening of the autoimmune disease.
Obstetric complications observed among the 70 en-
rolled pregnant women were observed in 29 cases
(41.4 %): abnormal fetal heart rate n = 7 (10 %), meco-
nium stained amniotic fluid n = 8 (10.7 %), oligohydram-
nios n = 3 (4.3 %), polyhydramnios n = 2 (2.9 %), threat
of preterm delivery n = 3 (4.3 %), IUGR n = 4 (5,71 %),
positive indirect Coombs test n = 2 (2.9 %).
Neonatal characteristics are reported in Table 2.
All the newborns were tested for maternal autoanti-
bodies at birth to assess the transplacental passage
(Table 3) and we didn’t observe significant differences
comparing data obtained from infants positive to mater-
nal autoantibodies (46 out of 70) vs those that were
negative (18 out of 70). No differences in obstetric and
perinatal complications (Table 4), mode of delivery, ges-
tational age, anthropometric parameters at birth and la-
boratory data, except for total bilirubin levels (7.2 vs
9.8 mg/dL, p = 0.05) were observed between infants posi-
tive to maternal autoantibodies and those negative. In
regard to the tested electrocardiographic values, no
differences were found in the two groups. We observed
that Ro/SSA and La/SSB autoantibodies crossed the pla-
cental barrier in 100 % of cases (Table 3) and five out
seven neonates with abnormal fetal heart rate were born
to mothers positive for anti-Ro/SSA (p = 0.01), of these
five neonates one was born to mothers treated with
hydroxychloroquine, one to mother with steroid and
three to mothers without therapy. Moreover, the routine
analysis of neonatal laboratory parameters of infants
born to mothers positive to anti-Ro/SSA versus infants
born to negative ones, didn’t show any statistically differ-
ence. We noted higher hemoglobin (p = 0.007), higher
hematocrit (p = 0.02) and higher total bilirubin levels (p
= 0.008) in the off-spring of negative mothers to anti-
Ro/SSA, all these values were however in normal ranges.
Moreover, maternal and neonatal ANA titre were
highly correlated as evaluated by the Spearman rho 0.74,
p < 0.001.
Thirty-seven (52.0 %) pregnant women received med-
ical therapy, they were treated with one or more drugs
for their autoimmune disease: 23 received steroid ther-
apy (prednisone), 9 received hydroxychloroquine, 17 re-
ceived low dose aspirin and 7 low molecular weight
heparin. Statistical analysis showed a higher incidence of
obstetrical (p = 0.007) and maternal (p = 0.002) compli-
cations in treated women than in non-treated ones, re-
lated to a higher incidence of preterm delivery (p = 0.06)
Table 2 Characteristics of infants enrolled in the study




Apgar score at 1′ and 5′, mean (SD) 9.0 (1.5) and 9.7 (0.9)
Cord pH, mean (SD) 7.27 (0.10)
Blood parameters,
White Blood Cells x103/μl, mean (± SD) 15.3 (5.9)
Neutrophils x103/μl, mean (± SD) 8.6 (4.5)
Hemoglobin g/dL, mean (± SD) 17.2 (2.0)
Hematocrit, % 51.6 (6.5)
Platelets x103/μl, mean (± SD) 270.9 (75.5)
Anthropometric data,
Weight at birth, mean (SD) 3045 gr (699)
LBWa number (%) 14 (20.0)
VLBWb number (%) 1 (1.4)
ELBWc number (%) 1 (1.4)
Length, mean (SD) 49 cm (3.5)
Head circumference, mean (SD) 34 cm (2.4)
IUGRd, number (%) 4 (5.7)
aLow Body Weight (Birth weight < 2500 g)
bVery Low Body Weight (Birth weight < 1500 g)
cExtremely Low Body Weight (Birth weight < 1000 g)
dIUGR Intrauterine growth restriction
Table 3 Autoantibodies detected in mothers and in the
newborns at birth
Autoantibodies Mothers (n = 70) Infants (n = 70) Placental transfer (%)
ANA 63 46 73
anti-SSA/Ro 22 22 100
anti-SSB/La 6 6 100
Othersa 3 0 0
aother autoantibodies
Table 4 Obstetric and perinatal events compared to
autoantibodies transplacental transfer
Obstetrical/perinatal events Autoantibodies placental transfer
Yes (n = 46) No (n = 18) P-value
Abnormal fetal heart rate 6 1 NS
Meconium stained amniotic fluid 5 3 NS
Oligohydramnios 1 2 NS
Polyhydramnios 2 0 NS
Threat of preterm delivery 1 2 NS
IUGR 3 1 NS
Positive indirect Coombs test 2 0 NS
Ventricular septal defect 1 0 NS
Cerebral alteration 4 4 NS
NS Not-Significant
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with low birth anthropometric parameters: weight (p =
0.003), length (p = 0.01) and head circumference (p =
0.004). In women undergoing both immunosuppressive
and anti-coagulant/anti-platelet therapy a significant
correlation with a higher incidence of IUGR newborns
compared to untreated women (p = 0.01) was registered.
Echocardiography revealed one case of ventricular sep-
tal defect in a IUGR preterm neonate.
Cerebral ultrasound scans revealed in 8 newborns the
following significant alterations: periventricular hypere-
chogenicity (n = 6), intraventricular hemorrhage which
resulted in pseudocysts or in multicystic leukomalacia
(n = 4), white matter leukodystrophy associated with
agenesis of the corpus callosum (n = 2). The statistical
analysis showed that these cases correlate significantly
with mother’s drug therapy, p = 0.005, but no correlation
was observed with the presence of anti-Ro/SSA, p = 0.4.
Discussion
Our observations, in agreement with data reported by
other authors, confirmed a higher frequency of miscar-
riages, of premature births and of low birth weight in-
fants born to women with autoimmune disease
compared to epidemiologic data of general obstetric
population in developed countries [11]. Moreover, we
confirmed previous literature data showing that the
placental barrier is crossed by antibodies: more than
70 % of ANA and 100 % of anti-Ro/SSA and anti-La/
SSB [12, 13].
The association of anti-Ro/SSA maternal positivity
with neonatal lupus complicated by the congenital sinus
bradycardia, first degree AV block or elongated QTc has
been reported [14]. Our findings, instead, did not reveal
any neonatal lupus disease in the off-spring from posi-
tive mothers. Nevertheless, a statistically significant cor-
relation between anti-Ro/SSA positive pregnancies and
abnormal fetal heart rate at the tococardiographic tra-
cing was detected (p = 0.01). The arrhythmogenic role of
anti-Ro/SSA and anti-La/SSB was established in animal
and in human [13, 15] this effect could promote CHB in
newborns of mothers Ro/SSA and/or La/SSA positive.
We therefore supposed that the CHB has possibly been
prevented by an adequate and carefully monitored
pharmacological treatment during pregnancy. In our
study, in fact, 73 % of the mothers anti-Ro/SSA positive
received a pharmacological treatment to control their
autoimmune disease.
To date, even if there is no full agreement about the
effects of immunosuppressive drugs on pregnancy and
on fetus/infant, high-dose of immunosuppressive treat-
ment administered to transplanted pregnant women has
been associated with a transient impairment of the im-
mune system of the newborn, increasing the risk of neo-
natal infections in the first months of life [16]. Other
authors carried out a study to evaluate relevant effects in
newborns and children born to women receiving immu-
nosuppressants for their autoimmune disorders. No rele-
vant effect on neonatal immune function, as evaluated
by complete blood count with differential white blood
cell count, immunoglobulin concentrations, lymphocyte
subpopulations, and later in response to hepatitis B vac-
cination were revealed [17]. In our study, as well, neither
neutropenia nor difference between white blood cells
and neutrophils count were reported in infants born to
treated women, compared to those born to untreated
mothers.
Furthermore, our findings revealed a statistical signifi-
cant higher incidence of obstetric and maternal compli-
cation in treated women compared to those untreated.
Previously, an increased risk of preterm delivery, low
birth weight and IUGR associated with immunosuppres-
sant therapy was reported by other authors [18].
We observed significantly lower values of neonatal an-
thropometric parameters at birth (weight, height and
head circumference) in the infants born to treated
mothers compared to untreated ones. Nevertheless we
have to remark that these infants had an earlier gesta-
tional age at birth too, which may be the reason of the
lower anthropometric measures. Interestingly, a higher
number of IUGR newborns (p = 0.01) was observed in
the group of women receiving polytherapy than in the
group of the untreated women. Unfortunately, we aren’t
able to conclusively address the correlation of this event
either with the polytherapy or with the worsening dis-
ease, requiring itself a more important therapy to con-
trol increasing symptoms. In fact both the conditions
coexist and are strictly linked.
Finally, the ultrasound evaluation showed cerebral al-
terations in 8 infants born to treated mothers, but these
alterations didn’t correlate to the mother’s positivity to
anti-Ro/SSA. Because the use of the drugs may be an in-
direct sign of the disease, it is unclear if the alterations
may be related to drug therapy, to the autoimmune dis-
ease or the results of the add up of these factors. These
data comply with the observations of Motta et al. [19]
that suggested no specific perinatal risk factor, but a
multi-factorial aetiology of brain abnormalities observed
in infants born to mothers with autoimmune disease.
A recent published review highlighted that the princi-
pal immunomodulant/immunosuppressive drugs admin-
istered during pregnancy have been shown to be
relatively safe, but the results are not conclusive [20].
Moreover, controlled clinical trials in pregnancy are not
ethical, therefore monitoring the pregnancy of these pa-
tients is the only available tool to have safety assessment.
In agreement with the cited authors we also hope that
international registries of the potential drug side effects
or of any useful information related to the pregnancy
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and the outcome of the off-spring will become common
and easily accessible over different countries [21]. Fur-
thermore, it must be considered that autoimmune dis-
eases could be undiagnosed before pregnancy because
the mild clinical illness that could be modified by the oc-
curring pregnancy that interferes with the immune sys-
tem. The administration of a screening questionnaire in
the first trimester of gestation has shown to be a useful
tool to identify in advance these subjects that could be
monitored carefully and, if necessary, managed the ap-
propriate therapy to proceed successfully with the preg-
nancy [22].
We have therefore to take care of this dichotomous as-
pect: monitoring and balancing the necessity to identify
and treat maternal disease and to preserve fetal health.
In fact, it is important to protect mother and fetus from
the hazard of increasing symptoms without, on the other
hand, compromising the newborn well-being with pos-
sible drug side effects.
We are aware of the limits of our study. The sample
size didn’t allow to create subgroups related to different
autoimmune diseases. Furthermore, we could not state if
the findings were related to maternal disease or to drugs
therapy or to others causative factors, such as genetic
features or neonatal independent circumstance (prema-
turity), because some of these conditions are very often
concomitant. Finally, we had not the opportunity to fol-
low the infants’ growth, therefore we have no informa-
tion about the possible sequelae afterward in childhood.
Conclusion
The take home message of this investigation is that preg-
nancy of mothers suffering for an autoimmune disease
has to be carefully monitored. Placental transfer of ma-
ternal autoantibodies, and the possible effects of mater-
nal therapy on the fetus/neonate are risk factors that
require a careful multidisciplinary management (gyne-
cologists, rheumatologists and neonatologists) to ensure
the best possible maternal and neonatal outcome Inter-
national registries describing the pattern of pregnancy
and the outcome of the off-spring could be an useful
tool to ameliorate the management of the mother/infant
dyad.
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